Glycogen Synthase Kinase 3 beta
"Glycogen Synthase Kinase 3 beta" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycogen synthase kinase-3 type enzyme that functions in ENERGY METABOLISM; EMBRYONIC DEVELOPMENT; and NEUROGENESIS. It is also involved in PROTEIN BIOSYNTHESIS and regulates cell growth and proliferation as a component of the WNT SIGNALING PATHWAY and other signaling pathways. Certain polymorphisms in the GSK3B gene have been associated with PARKINSON DISEASE; ALZHEIMER DISEASE; and BIPOLAR DISORDER.
Descriptor ID |
D000071679
|
MeSH Number(s) |
D05.500.117.875.500 D08.811.913.696.620.682.700.429.500.500 D08.811.913.696.620.682.700.646.625.500 D12.644.360.300.500.500 D12.776.476.081.875.500 D12.776.476.300.500.500
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glycogen Synthase Kinase 3 beta".
Below are MeSH descriptors whose meaning is more specific than "Glycogen Synthase Kinase 3 beta".
This graph shows the total number of publications written about "Glycogen Synthase Kinase 3 beta" by people in this website by year, and whether "Glycogen Synthase Kinase 3 beta" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 0 | 6 | 6 |
2004 | 0 | 8 | 8 |
2005 | 0 | 3 | 3 |
2006 | 0 | 3 | 3 |
2007 | 0 | 7 | 7 |
2008 | 0 | 10 | 10 |
2009 | 0 | 7 | 7 |
2010 | 0 | 12 | 12 |
2011 | 0 | 6 | 6 |
2012 | 0 | 6 | 6 |
2013 | 0 | 1 | 1 |
2015 | 1 | 4 | 5 |
2016 | 2 | 2 | 4 |
2017 | 3 | 3 | 6 |
2018 | 0 | 1 | 1 |
2019 | 2 | 4 | 6 |
2020 | 1 | 3 | 4 |
2021 | 1 | 1 | 2 |
2023 | 0 | 3 | 3 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glycogen Synthase Kinase 3 beta" by people in Profiles.
-
eEF1A2 promotes PTEN-GSK3?-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer. Sci Signal. 2024 Mar 05; 17(826):eadh4475.
-
GSK-3? as a Potential Coordinator of Anabolic and Catabolic Pathways in Hepatitis C Virus Insulin Resistance. Intervirology. 2024; 67(1):6-18.
-
Stabilization of E-cadherin adhesions by COX-2/GSK3? signaling is a targetable pathway in metastatic breast cancer. JCI Insight. 2023 03 22; 8(6).
-
Angiotensin II type 2 receptor activation preserves megalin in the kidney and prevents proteinuria in high salt diet fed rats. Sci Rep. 2023 03 15; 13(1):4277.
-
AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer. Cell Oncol (Dordr). 2022 Feb; 45(1):41-56.
-
GSK-3? Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. Cells. 2021 04 06; 10(4).
-
The GSK-3?-FBXL21 Axis Contributes to Circadian TCAP Degradation and Skeletal Muscle Function. Cell Rep. 2020 09 15; 32(11):108140.
-
T95 nucleophosmin phosphorylation as a novel mediator and marker of regulated cell death in acute kidney injury. Am J Physiol Renal Physiol. 2020 09 01; 319(3):F552-F561.
-
Drug Testing for Residual Progression of Diabetic Kidney Disease in Mice Beyond Therapy with Metformin, Ramipril, and Empagliflozin. J Am Soc Nephrol. 2020 08; 31(8):1729-1745.
-
OCIAD1 contributes to neurodegeneration in Alzheimer's disease by inducing mitochondria dysfunction, neuronal vulnerability and synaptic damages. EBioMedicine. 2020 Jan; 51:102569.